RxDoctor Payments Data

Thomas Sherman, MD

Psychiatry · Toledo, OHNPI 1790760163

Payments from drug & device makers

$982in general payments, 2019–2025

Across 59 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$353
  • Takeda Pharmaceuticals U.S.A., Inc.$174
  • Otsuka America Pharmaceutical, Inc.$122
  • Corium, LLC$107
  • Shire North American Group Inc$71
  • Alkermes, Inc.$70
  • plus $85 from 4 others

What the payments were for

  • Food & beverage$982100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$982 in reported general payments places this provider in the 70th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$85,237
Medicare patients
128
Services billed
1,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LatudaLurasidone Hcl12$25,126
VraylarCariprazine Hcl11$15,102
FetzimaLevomilnacipran Hcl19$11,876
TrintellixVortioxetine Hydrobromide12$10,102
Vilazodone Hcl43$5,320
Aripiprazole121$4,065
Duloxetine Hcl199$4,000
Alprazolam545$3,691
Fluoxetine Hcl341$3,526
Bupropion XlBupropion Hcl164$3,468
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine132$3,249
Buspirone Hcl212$2,956
Venlafaxine Hcl ErVenlafaxine Hcl132$2,812
Methylphenidate Hcl130$2,688
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine35$2,406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Fetzima$353$26,97830 claims
Sunovion Pharmaceuticals Inc.Latuda$32$25,12612 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$174$10,10212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →